Together with Professor David Nutt they will be talking about the beauty behind psychoactive substances as well as the, equally interesting, stories from Lady Feilding’s life journey.

Drug Science live podcast recording with Professor David Nutt!

If you want to find out how to travel to Ceylon for 25 pounds do have a listen!

Amanda Feilding is the Founder and Executive Director of the Beckley Foundation, and is widely recognised as a leading force behind the current Psychedelic Renaissance. By establishing key Research Programmes at some of the world’s most prestigious institutions (including Imperial College London, Maastricht University, Sant Pau in Barcelona, IDOR and UFRN in Brazil), she has propelled the field forward over the last 20+ years, conducting landmark studies, such as the world’s first psilocybin for treatment-resistant depression study (on which Compass Pathways based their business), the world’s first LSD, MDMA and DMT brain imaging studies, plus the initiation and collaboration with Johns Hopkins on the first study using psilocybin-assisted psychotherapy to overcome nicotine addiction. She has also co-authored over 80 research papers.

Since its inception in 1998, the Beckley Foundation has been at the forefront of exploratory research into psychedelics and cannabis, and evidence-based global drug policies. Through a series of pivotal international seminars at the House of Lords (starting in 2000) with leading figures from around the world in different fields, from science to politics, plus over 60 much-cited books, reports and papers, and numerous meetings with thought-leaders, academics, and policy-makers at the UN and governments around the world, Amanda has ensured that the Beckley Foundation has been at the forefront of global drug policy reform, particularly in the field of cannabis and the psychedelics.

Through her work with the Beckley Foundation, Amanda is bridging the gap between science and policy, creating a positive feedback loop, with the aim of building and harnessing our knowledge of the benefits of currently prohibited compounds to optimise human health, wellbeing and potential.